// App-Quantinova.ai

FRI0343 : EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)

Researchers

Presenter

  • P. Helliwell

Principal Investigators

  • F. Van den Bosch

  • L. C. Coates

  • D. D. Gladman

  • C. Tasset

  • L. Meuleners

  • L. Gilles

  • L. Gheyle

  • M. Trivedi

  • M. Alani

  • R. Besuyen

  • P. J. Mease

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • Ghent University Hospital, Ghent, Belgium

  • NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  • Galapagos, Mechelen, Belgium

  • LACO, contracted by Galapagos NV, Mechelen, Belgium

  • Gilead Sciences, Inc., Foster City, CA, United States.

  • University of Washington, Washington, United States of America

  • Galapagos, Nv, Leiden, The Netherlands

  • Swedish Medical Centre, Seattle, United States of America

Locations

  • United Kingdom

  • Belgium

  • Canada

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • II

Study Id's

  • NCT03101670

Sponsors

  • Galapagos and Gilead Sciences

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved